首页> 外文期刊>The journal of clinical psychiatry >Aripiprazole and worsening of psychosis: a case report.
【24h】

Aripiprazole and worsening of psychosis: a case report.

机译:阿立哌唑与精神病恶化:一例报告。

获取原文
获取原文并翻译 | 示例
           

摘要

Sir: Crossman and Lindenmayer1 describe 4 cases of high-dose aripiprazole in treatment-refractory schizophrenia, among which 1 showed improvement and all tolerated the drug satisfactorily. As a counterpoint to that report, we report worsening of psychosis, temporally associated with aripiprazole use, and offer our comments on relapse seen on introducing aripiprazole in the presence of other antipsychotics and thus the need for careful cross-titration at any drug dosage. Aripiprazole is a new atypical antipsychotic with partial D_2- and 5-HT_(1A)-agonist properties and 5-HT_(2A)-antagonist properties. It is a functional D_2-antagonist under hyperdopaminergic conditions, but a functional D_2-agonist under hypodopaminergic conditions. It appears to be generally well tolerated, with a favorable side effect profile.
机译:主席先生:Crossman和Lindenmayer1描述了4例治疗难治性精神分裂症大剂量阿立哌唑的病例,其中1例表现出改善并且对药物的耐受性良好。作为该报告的对立面,我们报告了与阿立哌唑在时间上相关的精神病恶化,并就在存在其他抗精神病药的情况下引入阿立哌唑所见的复发发表了评论,因此,在任何药物剂量下均需仔细交叉滴定。阿立哌唑是一种新型的非典型抗精神病药,具有部分D_2-和5-HT_(1A)-激动剂特性和5-HT_(2A)-拮抗剂特性。它在高多巴胺能的条件下是功能性的D_2-拮抗剂,但在低多巴胺能的条件下是功能性的D_2-激动剂。它似乎通常具有良好的耐受性,并具有良好的副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号